RXR Nuclear Receptor Agonists Promote Clearance of Alpha-Synuclein in Cellular Models
· Financial Post
Investigators Present Data Supporting Disease-Modifying Potential of the Io Therapeutics RXR Agonist Compound IRX4204 in Parkinson’s Disease Read More
Visit newsbetsport.bond for more information.